Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | ALB | P02768 | 3/20 | 0.62 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.62 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL21100417 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL10380711 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3715526 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL9194365 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3598 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL12149465 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL8094882 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3235525 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL27555151 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL29277683 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025128741-A1 | OCTADECANOID COMPOSITIONS AND METHODS OF ACTIVATING MUCOSAL REPAIR PATHWAYS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2021231872-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | HEALION BIO, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-1997048701-A1 | 4,1-BENZOXAZEPINES OR 4,1-BENZOTHIAZEPINES AND THEIR USE AS SQUALENE SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5631239-A | VIRICIDES FOR HEPATITIS | YALE UNIVERSITY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5627160-A | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents | YALE UNIVERSITY (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0765665-A1 | Use of dideoxy nucleoside analogues in the treatment of viral infections | BIOCHEM PHARMA INC (CA) | 1997-04-02 | — | — | EP | disclosed |
| US-5561120-A | LOW TOXICITY TO HOST CELLS | YALE UNIVERSITY (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0707481-A4 | — | — | 1996-05-29 | — | — | EP | disclosed |
| EP-0707481-A1 | L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1994027616-A1 | L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | LMNA 4428/4885PDE3A 521/4885ALB 852/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | LMNA 1694/4885PDE3A 1432/4885ALB 1282/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | LMNA 4428/4885PDE3A 521/4885ALB 852/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | LMNA 3091/4885PDE3A 136/4885ALB 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.